Skip to main content

GeneNews Raises $6.7M in Private Placement

NEW YORK (GenomeWeb) – GeneNews today announced it has accepted subscriptions for a non-brokered private placement of its common shares for gross proceeds of about C$7.2 million (US$6.7 million).

The Toronto-based molecular diagnostics shop will issue 7 million common shares at C$1.03 per share as a result of the placement, which GeneNews announced last week. In a statement, GeneNews Executive Chairman James Howard-Tripp said that the financing provides the company with the resources to build out Innovative Diagnostics Laboratory "as a strong commercialization outlet" for the firm's molecular diagnostic tests for colon cancer, lung cancer, and prostate cancer.

IDL is a CLIA laboratory jointly owned by GeneNews, Health Diagnostics Laboratory, and an unnamed US sales organization.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.